Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections

To assess the pharmacokinetic and pharmacodynamic (PK/PD) properties of voriconazole and to investigate the relationship between PK/PD parameters and the efficacy of a fixed‐dose oral regimen in the treatment of invasive fungal infections (IFIs).

[1]  F. Dromer,et al.  Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010 , 2014, Emerging infectious diseases.

[2]  R. Gorton,et al.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. , 2014, The Journal of antimicrobial chemotherapy.

[3]  J. Xing,et al.  Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. , 2014, The Journal of antimicrobial chemotherapy.

[4]  M. Valach,et al.  Fungal neuroinfections and fungaemia: unexpected increase of mortality from invasive fungal infections in 2005-2011 in comparison to 1989-1998: analysis of 210 cases. , 2013, Neuro endocrinology letters.

[5]  P. G. Choe,et al.  The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  T. Buclin,et al.  Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  G. Guaraldi,et al.  Fusarium verticillioides fungemia in a liver transplantation patient: successful treatment with voriconazole. , 2011, Diagnostic microbiology and infectious disease.

[8]  P. Troke,et al.  Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients , 2011, Antimicrobial Agents and Chemotherapy.

[9]  M. Pai,et al.  Steady-State Plasma Pharmacokinetics of Oral Voriconazole in Obese Adults , 2011, Antimicrobial Agents and Chemotherapy.

[10]  M. Romkes,et al.  Voriconazole Pharmacokinetics in Liver Transplant Recipients , 2009, Antimicrobial Agents and Chemotherapy.

[11]  P. Chandrasekar,et al.  Antifungal drugs: predicting clinical efficacy with pharmacodynamics , 2009, Expert review of clinical pharmacology.

[12]  Kazuaki Matsumoto,et al.  Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. , 2009, International journal of antimicrobial agents.

[13]  M. Kurokawa,et al.  Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders , 2009, International journal of hematology.

[14]  W. Haefeli,et al.  CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole , 2009, Journal of clinical pharmacology.

[15]  Liuda Ziaugra,et al.  SNP Genotyping Using the Sequenom MassARRAY iPLEX Platform , 2009, Current protocols in human genetics.

[16]  J. Perfect,et al.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  H. Lipp Antifungal agents – clinical pharmacokinetics and drug interactions , 2008, Mycoses.

[19]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  S. Ranque,et al.  Contribution of the (1→3)-β-d-Glucan Assay for Diagnosis of Invasive Fungal Infections , 2007, Journal of Clinical Microbiology.

[21]  L. Gordon,et al.  Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients , 2007, Cancer.

[22]  K. Sepkowitz,et al.  Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  T. Buclin,et al.  Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods , 2006, Antimicrobial Agents and Chemotherapy.

[24]  Peter G. Pappas,et al.  Invasive Fungal Pathogens: Current Epidemiological Trends , 2006 .

[25]  R. Herbrecht,et al.  Clinical pharmacokinetics of voriconazole. , 2006, International journal of antimicrobial agents.

[26]  M. Ghannoum,et al.  Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints , 2006, Journal of Clinical Microbiology.

[27]  E. Thiel,et al.  Improved outcome in central nervous system aspergillosis, using voriconazole treatment. , 2005, Blood.

[28]  S. Balajee,et al.  Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. , 2004, The Journal of infectious diseases.

[29]  M. Nakashima,et al.  Pharmacokinetics of Voriconazole and Cytochrome p450 2C19 Genetic Status , 2004, Clinical pharmacology and therapeutics.

[30]  D. Andes,et al.  In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[31]  D A Smith,et al.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[32]  S. Gershon,et al.  Effects of chronic chlorpromazine administration on systemic arterial pressure in schizophrenic patients: Relationship of body position to blood pressure , 1965, Clinical pharmacology and therapeutics.

[33]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .

[34]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[35]  L. Scott,et al.  Voriconazole : a review of its use in the management of invasive fungal infections. , 2007, Drugs.

[36]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.